Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers September 24, 2017
Pharmacy Choice - Pharmaceutical News - Implanet Announces Clearance of the New JAZZ? Passer - September 24, 2017

Pharmacy News Article

 9/12/17 - Implanet Announces Clearance of the New JAZZ? Passer

FDA clearance granted in the US for the new system devoted to posterior fixation in spine surgery, compatible with all JAZZ? Platform implants

BORDEAUX, France & BOSTON(BUSINESS WIRE)

Regulatory News:

IMPLANET (Euronext Growth: ALIMP, FR0010458729, PEA-PME eligible) (Paris:IMPL) (OTCQX:IMPZY), a medical technology company specializing in vertebral and knee-surgery implants, today announces that it has received FDA clearance to market the new JAZZ? Passer.

JAZZ? Passer comprises new passer instruments and a variation of the JAZZ? Band braid, the JAZZ? Passer Band. The latter is 100% compatible with all JAZZ? platform implant connectors, and replicates the mechanical performances of the innovative JAZZ? Band braid, highlighted in numerous scientific publications.

JAZZ? Passer facilitates placing the band around anatomical structures, representing a breakthrough in terms of flexibility and ease of use. This simplified system should drive surgeon adoption of JAZZ? band technologies.

This comprehensive system was designed in direct response to surgeon feedback. Implanet addresses an ever-expanding list of therapeutic indications, given the characteristics and performance of the JAZZ? Platform. By effectively covering all degenerative, scoliosis-deformity and trauma-tumor pathologies in adolescents and adults, the Company competes in a market segment estimated at over 2 billion dollars.

Rgis Le Couedic, Implanet's Product Development & Manufacturing Director, says: This project's challenge lay in the need to retain our JAZZ? technology's proprietary performance characteristics. Our goal was also to develop simple instrumentation that provides the surgeon tactile feel when passing the braid around bony structures. Our valued surgeon advisors confirm that this twofold objective has been achieved, with the combination of the new braid and passers making it even easier to use JAZZ?, notably in the areas of degenerative and complex spine surgery, which account for most spine operations.

Regarding this new product launch, Nicolas Marin, Implanet's Chief Marketing Officer, adds: The JAZZ? Passer systems enables us to reach a new milestone in the adoption of our technology and the frequency of its use by surgeons. With 20% market share in pediatric deformity surgery in France, we feel that the use of JAZZ? band technologies has become standard of care and will be part of the therapeutic arsenal of many surgeons in the rest of the world. JAZZ? Passer represents the most appropriate response to the various problems encountered by spine surgeons that only our technology makes it possible to truly address, illustrated by the conversion of new user surgeons, particularly in the United States.

Next financial press release: H1 2017 results, on September 19, 2017 after market closes

About IMPLANET

Founded in 2007, IMPLANET is a medical technology company that manufactures high-quality implants for orthopedic surgery. Its flagship product, the JAZZ? latest-generation implant, aims to treat spinal pathologies requiring vertebral fusion surgery. Protected by four families of international patents, JAZZ? has obtained 510(k) regulatory clearance from the Food and Drug Administration (FDA) in the United States and the CE mark. IMPLANET employs 48 staff and recorded 2016 sales of ?7.8 million. For further information, please visit www.implanet.com. Based near Bordeaux in France, IMPLANET established a US subsidiary in Boston in 2013. IMPLANET is listed on Euronext? Growth market in Paris.

Disclaimer

This press release contains forward-looking statements concerning Implanet and its activities. Such forward looking statements are based on assumptions that Implanet considers to be reasonable. However, there can be no assurance that the anticipated events contained in such forward-looking statements will occur. Forward- looking statements are subject to numerous risks and uncertainties including the risks set forth in the registration document of Implanet registered by the French Financial Markets Authority (Autorit des marchs financiers (AMF)) on April 26, 2016 under number R.16-035 and available on the Company's website (www.implanet-invest.com), and to the development of economic situation, financial markets, and the markets in which Implanet operates. The forward-looking statements contained in this release are also subject to risks unknown to Implanet or that Implanet does not consider material at this time. The realization of all or part of these risks could lead to actual results, financial conditions, performances or achievements by Implanet that differ significantly from the results, financial conditions, performances or achievements expressed in such forward-looking statements. This press release and the information it contains do not constitute an offer to sell or to subscribe for, or a solicitation of an order to purchase or subscribe for Implanet shares in any country.

IMPLANET

Ludovic Lastennet, +33 (0)5 57 99 55 55

CEO

investors@implanet.com

or

NewCap

Investor Relations

Florent Alba, +33 (0)1 44 71 94 94

implanet@newcap.eu

or

NewCap

Media Relations

Nicolas Merigeau, +33 (0)1 44 71 94 98

implanet@newcap.eu

or

AlphaBronze

US-Investor Relations

Pascal Nigen, +1 917 385 21 60

implanet@alphabronze.net

Source: IMPLANET



Copyright Business Wire 2017

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

LIVE ONLINE CE

Last Chance
Sep 25: Management of Major Depressive Disorders
Sep 26: Vitamins, Minerals, and Electrolytes in Older Adults
Sep 27: Medication Use During Pregnancy & Lactation
Sep 28: An Integrative Approach to Managing Arthritis
Sep 29: Legal & Practical Issues in Compounding Pharmacy
Click for entire Webinar Calendar

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...

Nursing Jobs
Are you a nurse looking for a job?

Check out the Nursing Job Source.

Your number one choice for nursing jobs.



Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2017 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415